P3424 - Acute Pancreatitis in End-Stage Renal Disease: A Nationwide Database Study

Chloe Lahoud, MD¹, Taqi Rizvi, DO¹, Mark Tawfik, DO¹, Gennifer Wahbah Makhoul, MD¹, Suzanne El-Sayegh, MD^2
1Staten Island University Hospital, Northwell Health, Staten Island, NY; ²Staten Island University Hospital, Staten Island, NY

Introduction: Acute pancreatitis (AP) is one of the most common gastrointestinal diseases that require hospitalization. The incidence of AP ranges from 13 to 45 per 100,000 persons in the US. In ESRD, AP poses a challenging diagnosis and requires a tailored therapeutic approach. In this study, we aim to assess endoscopic retrograde cholangiopancreatography (ERCP) rates, length of stay and mortality rates in ESRD patients with AP compared to non-ESRD patients with AP.

Methods: Data for hospitalized patients with acute pancreatitis was obtained from The National Inpatient Sample (NIS) database from 2016-2018. Baseline risk factors were identified using ICD-10 codes. Patients were stratified into two groups based on the presence of ESRD. A 1:1 propensity score matching was utilized based on selected risk factors between ESRD and non-ESRD patients and a regression analysis was performed on the matched cases.

Results: Out of 172,601 patients with acute pancreatitis, 8,470 patients were included in the analysis after performing 1:1 propensity score matching based on selected baseline characteristics and risk factors. On regression analysis patients with acute pancreatitis and ESRD compared to non-ESRD patients had lower rates of ERCP performed (Odds ratio=0.454, P=0.014, 95% CI 0.241-0.854). Patients with ESRD who developed AP had a longer hospital stay (Odds radio=1.029, P= < 0.001, 95% CI 1.023-1.035) and had a higher mortality rate (Odds ratio=1.547, P=< 0.001, 95% CI 1.225-1.954) in comparison to non-ESRD patients.

Discussion: Patients with ESRD who develop AP have lower rates of ERCP performed, longer hospital stays and increased mortality rates. Further research on AP in ESRD patients is essential to develop a tailored therapeutic approach addressing the challenges and contributing to better outcomes within this patient population.


Disclosures:


Chloe Lahoud, MD¹, Taqi Rizvi, DO¹, Mark Tawfik, DO¹, Gennifer Wahbah Makhoul, MD¹, Suzanne El-Sayegh, MD². P3424 - Acute Pancreatitis in End-Stage Renal Disease: A Nationwide Database Study, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.